Table 3.
The viability between groups with different concentrations and at different times.
| Groups | Concentrations (μg) | Time | P value | ||
|---|---|---|---|---|---|
| 30 min | 90 min | 180 min | |||
| Essential oil | 1 10 50 100 500 1000 |
98.64 ± 1.52 79.58 ± 1.00 76.53 ± 1.52 75.53 ± 1.15 74.53 ± 1.15 73.85 ± 1.15 |
96.42 ± 2.26 77.36 ± 2.63 74.31 ± 2.63 73.31 ± 2.63 72.31 ± 3.11 71.63 ± 2.11 |
92.20 ± 1.52 75.14 ± 2.08 72.19 ± 2.00 71.19 ± 2.51 69.19 ± 2.51 67.41 ± 2.51 |
0.631 |
|
| |||||
| P value | <0.001 | <0.001 | <0.001 | ||
|
| |||||
| Sulfadiazine (positive control) | 1 10 50 100 500 1000 |
98.66 ± 0.57 89.33 ± 0.57 85.66 ± 1.52 84.00 ± 2.00 83.66 ± 1.52 82.33 ± 2.08 |
92.66 ± 0.02 88.22 ± 0.006 84.97 ± 0.03 83.27 ± 0.01 82.68 ± 0.03 81.93 ± 0.00 |
88.66 ± 1.52 71.00 ± 1.00 68.66 ± 1.15 67.66 ± 1.52 65.66 ± 2.08 63.33 ± 1.52 |
0.001 |
|
| |||||
| P value | <0.001 | <0.001 | <0.001 | ||
|
| |||||
| Pyrimethamine (positive control) | 1 10 50 100 500 1000 |
98.66 ± 1.52 93.33 ± 2.08 85.33 ± 3.05 83.00 ± 2.00 81.00 ± 2.00 75.33 ± 1.52 |
92.03 ± 0.01 86.46 ± 0.02 82.07 ± 0.00 81.85 ± 0.01 80.21 ± 0.00 70.61 ± 0.00 |
84.66 ± 2.51 70.66 ± 2.08 67.33 ± 2.51 65.66 ± 1.52 64.33 ± 2.51 62.00 ± 3.00 |
0.005 |
|
| |||||
| P value | <0.001 | <0.001 | <0.001 | ||
|
| |||||
| Negative | — | 97.00 ± 1.00 | 95.33 ± 2.51 | 95.33 ± 1.15 | 0.958 |